Mabwell's 9MW2821 Shows Strong Clinical Efficacy in Bladder Cancer Trials
Event summary
- Mabwell will present Phase Ib/II and Phase II clinical data for 9MW2821 at the 2026 ASCO Annual Meeting.
- Phase Ib/II trial for la/mUC showed an 83.0% ORR and 12.9-month median PFS in combination with toripalimab.
- Phase II trial for perioperative MIBC achieved a 66.7% pCR rate with the same combination.
- 9MW2821 has received multiple FDA designations, including Fast Track and Breakthrough Therapy.
The big picture
Mabwell's 9MW2821 represents a competitive entry in the Nectin-4-targeting ADC space, with strong Phase II data positioning it against established therapies. The company's ability to secure multiple regulatory designations underscores the clinical potential of its candidate. Success in pivotal Phase III trials could significantly expand Mabwell's oncology portfolio, particularly in urothelial carcinoma and cervical cancer where treatment options remain limited.
What we're watching
- Regulatory Momentum
- Whether interim Phase III data in 2026 will support pre-NDA meetings for urothelial carcinoma and cervical cancer indications.
- Clinical Pipeline Expansion
- The pace at which Mabwell advances its Phase III trials across multiple cancer indications.
- Commercialization Strategy
- How Mabwell positions 9MW2821 against existing Nectin-4-targeting ADCs in the global oncology market.
Related topics